


Product Name : BLU-667
Cat. No. : PC-63475
CAS No. : 2097132-94-8
Molecular Formula : C₂₇H₃₂FN₉O₂
Molecular Weight : 533.612
Target : RET Tyrosine Kinase (c-RET)
Solubility : 100 mM in DMSO (53.3 mg/mL)



2. Piotrowska Z, et al. **Cancer Discov.** 2018 Dec;8(12):1529-1539.

Biological Activity

BLU-667 (Pralsetinib, BLU667) is a highly potent, selective, next generation **RET** inhibitor with IC₅₀ of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion.

BLU-667 displays 8- to 28-fold more potent against WT RET than cabozantinib, vandetanib, and RXDX-105; shows 88-fold selectivity over VEGFR-2, >100-fold more selective for RET over 96% of kinases in a panel of 371 kinases.

BLU-667 inhibits RET autophosphorylation with cellular IC₅₀ of 5 nM, at least 10 times more potently than cabozantinib, vandetanib, and RXDX-105.

BLU-667 inhibits phosphorylation of RET, SHC, and ERK1/2 in a panel of RET-driven cell lines at <10 nM, suppresses proliferation of KIF5B-RET Ba/F3 cells harboring V804L, V804M, or V804E variants as potently as WT RET.

BLU-667 demonstrates antitumor activity on diverse RET-driven in vivo models.

References

Subbiah V, et al. **Cancer Discov.** 2018 Apr 15. pii: CD-18-0338.

